期刊文献+

子痫前期孕妇血细胞比容、sVEGFR-1水平与围生儿结局比较 被引量:2

Comparison Between Preeclampsia Hematocrit,Soluble Vascular Endothelial Growth Factor Receptor-1 and Perinatal Outcomes
下载PDF
导出
摘要 目的 通过对子痫前期患者产前血细胞比容(HCT)、血中sVEGFR-1水平的改变探讨其对围生儿结局的影响.方法 对2011年7月~2012年1月在辽宁朝阳市中心医院入院的41例子痫前期患者和19名正常妊娠者采集一般状况,用电子血细胞自动计数仪测静脉血的血细胞比容;采用酶联免疫测定(ELISA)试剂盒检测血清中sVEGFR-1水平.记录所有胎儿出生体重、Apagar评分,用Pearson检验进行相关性分析.结果 子痫前期组与正常妊娠组比较,孕期明显缩短(P <0.001).无论收缩压还是舒张压均明显高于正常妊娠组(P <0.001),子痫前期组HCT明显增高(P<0.001),血清sVEGFR-1水平亦明显升高(P<0.05),其中子痫前期早发型升高最显著(P <0.001),23例早发型组中7例采用引产终止妊娠.围生儿出生体重子痫前期组明显低于正常新生儿组(P<0.05),其中以早发型组最低,与正常或晚发型组差异明显(P<0.001).此外,产后1min的Apagar评分正常新生儿19例全部是满分(10分),明显高于子痫前期组(P<0.001).Pearson检验显示,产前孕妇血清sVEGFR-1水平与围生儿出生体重呈明显的负相关(P<0.01,r=-0.54).结论 本研究发现子痫前期HCT明显增高,产前孕妇血中sVEGFR-1水平与围生儿出生体重呈明显负相关,对预测子痫及其母婴预后有重要参考价值. Objective To compare Hematocrit(HCT) , Soluble Vascular Endothelial Growth Factor Receptor - 1 ( sVEGFR - 1 ) in pregnant women with preeclampsia and perinatal outcomes. Methods Folty - one preeclamptic patients and nineteen normal pregnantwomen in Chaoyang Central Hospital, Liaoning province from July 2011 to January 2012 were enrolled in the study. Automatic counting cell instrument was used for measuring HCT in the venous blood. The serum sVEGFR - 1 levels in all the subjects were analyzed with ELISA method respectively. All fetal birth weight, Apagar score were also recorded. The correlation analysis was performed with Pearson test. Results Pregnancy was significantly shorter (P 〈 0. 001 ) in Preeclampsia when compared with normal pregnancy group. Either systolic or diastolic blood pressure was significantly higher than that of normal pregnancy group (P 〈 0. 001 ). HCT significantly increased (P 〈0.001 ) in preeclampsia group. The serum sVEGFR- 1 was also significantly higher (P 〈 0. 05 ). The early onset preeclampsia increased most significantly ( P 〈 0. 001 ). 7 cases of termination of pregnancy in 23 - early onset group were used by induced abortion. Peri- natal birth weight in preeclampsia group were significantly lower than those in normal neonate group (P 〈 0.05 ). The early onset group was the lowest, when compared with normal or late onset group (P 〈0. 001 ). In addition, Apagar score of postpartum lmin in 19 normal neonates was full mark (10) , higher than those in preeclampsia group (P 〈0. 001 ). Pearson test showed that serum sVEGFR - 1 levels in pregnant women were obviously negatively correlated with perinatal birth weight (P 〈 0.01, r = - 0.54). Conclusion This study found that HCT of preeclampsia was significantly higher,sVEGFR - 1 levels in the blood of pregnant women were obviously negatively correlated with perinatal birth weight, which could be beneficial for predicting the preeclampsia prognosis and perinatal outcome.
出处 《医学研究杂志》 2014年第6期122-125,共4页 Journal of Medical Research
关键词 子痫前期 血细胞比容 可溶性血管内皮生长因子受体-1(sVEGFR-1) 围生儿结局 Preeclampsia Hematocrit Soluble vascular endothelial growth factor receptor- 1 (sVEGFR- 1 ) Perinatal Outcomes
  • 相关文献

参考文献7

  • 1Vatten LJ,fisvold BO,Eskild A.Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction[J].Acta Obstet Gynecol Scand,2012,91 (12):1389-1394.
  • 2Lea(n)os MA,Campos GI,Ramírez V KL,et al.Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia[J].Hypertension,2013,61 (5):1118-1125.
  • 3LevenoKJ.Cunningham FG,Alexander JM.威廉姆斯产科学手册:妊娠并发症[M].龚晓明,边旭明译.北京:人民卫生出版社,2008:155.
  • 4Kramer MS,Platt RW,Wen SW,et al.A new and improved population-based Canadian reference for birth weight for gestational age[J].Pediatrics,2001,108:E35.
  • 5Girardi G,Yarilin D,Thurman JM,et al.Complement activation induces dysregulation of preeclampsia[J].Nat M ed,2006,12:642-649.
  • 6Paasche R MC,Lorentzen B,Godang K,et al.Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1),but not in soluble endoglin concentrations in preeclampsia[J].Placenta,2012,33(3):224-226.
  • 7袁小松,张一鸣,蒋雅琴,蒋丽霞.血清可溶性血管内皮生长因子受体1/胎盘生长因子比值作为预测子痫前期患病风险的价值[J].检验医学,2010,25(10):784-786. 被引量:8

二级参考文献8

  • 1乐杰主编.妇产科学[M].第7版.北京:人民卫生出版社,2009.271-272.
  • 2Sibai B,Dekker G,Kupferminc M.Pre-eclampsia[J].Lancet,2005,365(9461):785-799.
  • 3Levine RJ,Maynard SE,Qian C,et al.Circulating angiogenic factors and the risk of preeclampsia[J].N Engl J Med,2004,350(7):672-683.
  • 4Chaiworapongsa T,Romero R,Kim YM,et al.Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia[J].J Matern Fetal Neonatal Med,2005,17(1):3-18.
  • 5Romero R,Nien JK,Espinoza J,et al.A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate[J].J Matern Fetal Neonatal Med,2008,21(1):9-23.
  • 6Moore Simas TA,Crawford SL,Solitro MJ,et al.Angiogenic factors for the prediction of preeclampsia in high-risk women[J].Am J Obstet Gynecol,2007,197(3):244.e1-244.e8.
  • 7Koga K,Osuga Y,Yoshino O,et al.Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia[J].J Clin Endocrinol Metab,2003,88(5):2348-2351.
  • 8Chaiworapongsa T,Romero R,Espinoza J,et al.Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia[J].Am J Obstet Gynecol,2004,190(6):1541-1547.

共引文献7

同被引文献26

  • 1Christelle Orlando, Olivier Heylen, Willy Lissens, et al. Antithrombin heparin binding site deficiency: a challenging diagnosis of a not so benign thrombophilia[J].Thrombosis Research, 2015, 135 (6): 1179-1185.
  • 2Kaga M, Li H, Ohta H, et al.Liposome-encapsulated hemoglobin ( hemoglobin-vesicle ) is not transferred from mother to fetus at the late stage of pregnancy in the rat model[J].Life Sciences, 2012, 91 (12) : 420-428.
  • 3Wang K, Luo H, Xin Y, et al. Successful pregnancy and delivery in patients with uncorrected single ventricle: Three new cases and literature review[J].International Journal of Cardiology, 2015, 184 ( 1 ) : 135-139.
  • 4Tiralongo G M, Lo Presti D, Pisani I, et al. Assessment of totalvascular resistance and total body water in normotensive women during the first trimester of pregnancy. A key for the prevention of preeclampsia[J].Pregnancy Hypertensions, 2015, 5 ( 2 ) : 193- 197.
  • 5Rodger M A, Hague W M, Kingdom J, et al. Antepartum dalteparin versus no antepartum daheparin for the prevention of pregnancy complications in pregnant women with thrombophilia ( TIPPS ) : a multinational open-label randomised trial[J].The Lancet, 2014, 384 (9955) : 1673-1683.
  • 6Rodger M A. An update on thrombophilia and placenta mediated pregnancy complieations: what should we tell our patients? [J]. Thrombosis Research, 2013, 131 (Suppl 1 ) : $25-27.
  • 7Patil R, .Ghosh K, Vora S, et al. Inherited and acquiredthrombophilia in Indian women experiencing unexplained recurrent pregnancy loss[J].Blood Cells Mol Dis, 2015, 55 ( 3 ): 200-205.
  • 8Ziakas P D, Poulou L S, Pavlou M, et al. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk[J].Eur J Obstet Gynecol Reprod Biol, 2015, 191 (2) : 106-111.
  • 9Hossain N, Paidas M J. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy[J].Clin Lab Med, 2013, 33 ( 2 ) : 377-390.
  • 10Wang K, Luo H, Xin Y, et al. Successful pregnancy and delivery in patients with uncorrected single ventricle : Three new cases and literature review[J].Int J Cardiol, 2015, 184: 135-139.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部